Bayer stock rises 1.54 percent as targets point higher

Published on 09/25/2026 at 11:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock trades at EUR 50.14 on September 25, 2026, below its EUR 53.92 yearly high. Barclays lifted its target from EUR 60 to EUR 70 on September 7, 2026.

Forscherin im weißen Kittel pipettiert an einem beleuchteten Laborarbeitsplatz vor einem Bildschirm mit 3D-Molekülstruktur — Pharmazeutisches Forschungslabor – Wissenschaftlerin mit Pipette, Molekülstruktur-Monitor, blaue LED-Beleuchtung, Illustration mit AI erstellt.

Bayer stock (ISIN DE000BAY0017) traded at EUR 50.14 on Xetra on September 25, 2026, up 1.54 percent from the previous close of EUR 49.38. The move puts the share within 7.01 percent of its 52-week high of EUR 53.92, while the market capitalization stands at EUR 49,258,743,471.

September 25 brings a 1.54 percent rise

The intraday range on Xetra ran from EUR 49.16 to EUR 50.32, with volume at 476,120 shares as of September 25, 2026. The price remains 94.49 percent above the 52-week low of EUR 25.78, giving the stock a wide trading band even after its latest advance.

For investors, the immediate technical reference is the EUR 53.92 yearly high. A move from EUR 50.14 to that level would require a 7.54 percent gain, based on the same September 25 market snapshot.

Barclays raises target to EUR 70

Barclays raised its Bayer price target from EUR 60 to EUR 70 and reiterated its Overweight rating in a research update published on September 8, 2026, based on an original study dated September 7, 2026, according to MarketScreener.

The new target is EUR 19.86 above the September 25 price, or 39.61 percent higher. Barclays analyst James Gordon linked the potential re-rating to progress on Bayer's glyphosate litigation, while the rating itself remained Overweight, the same report said.

Q2 2026 results set the next checkpoint

Bayer's investor-relations page identifies the second-quarter 2026 results as the latest featured report and describes the group as operationally on track in its strategic priorities, according to Bayer.

The company combines Crop Science, Pharmaceuticals and Consumer Health. The investor-relations page highlights 2026 key figures, innovation pipelines and market opportunities, making the next reported operating update important for testing whether the market's valuation can move closer to the EUR 70 analyst target.

Stock stays below its yearly high

Bayer stock was trading at EUR 50.14 on Xetra at 11:27 a.m. CEST on September 25, 2026, with a 1.54 percent intraday gain and a EUR 53.92 52-week high as the next major reference level.